-
Start Preamble
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Final rule.
SUMMARY:
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during February 2012. FDA is also informing the public of the availability of summaries of the basis of approval and of environmental review documents, where applicable.
DATES:
This rule is effective May 3, 2012.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9019, email: george.haibel@fda.hhs.gov.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
FDA's Center for Veterinary Medicine is adopting the use of a monthly Federal Register document to codify approval actions for NADAs and ANADAs. CVM will no longer publish a separate rule for each action. This approach will allow a more efficient use of available resources.
In this document, FDA is amending the animal drug regulations to reflect the original and supplemental approval actions during February 2012, as listed in table 1 of this document. FDA is also informing the public of the availability of summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA) and of environmental review documents required under the National Environmental Policy Act (NEPA), where applicable.Start Printed Page 26162
Table 1—Original and Supplemental NADAs and ANADAs Approved During February 2012
NADA/ ANADA Sponsor New animal drug product name Action 21 CFR Section FOIA Summary NEPA Review 141-328 Merial Ltd., 3239 Satellite Blvd., Bldg. 500, Duluth, GA 30096-4640 ZACTRAN (gamithromycin) Injectable Solution Supplement adding treatment of bovine respiratory disease (BRD) associated with M. bovis 522.1014 yes CE1 141-209 Pharmacia & Upjohn Co., a Division of Pfizer, Inc., 235 East 42d St., New York, NY 10017 EXCEDE (ceftiofur crystalline free acid) Sterile Suspension Supplement adding treatment of acute bovine metritis in lactating dairy cows; and modified injection techniques 522.313a yes CE 200-484 Huvepharma AD, 33 James Boucher Blvd., Sophia 1407, Bulgaria TYLOVET 100 (tylosin phosphate) Type A medicated Article Original approval as generic copy of NADA 012-491 558.625 yes CE 1 The Agency has determined under 21 CFR 25.33 that this action is categorically excluded (CE) from the requirement to submit an environmental assessment (EA) or an environmental impact statement (EIS) because it is of a type that does not individually or cumulatively have a significant effect on the human environment. The basis of approval of actions requiring review of safety or effectiveness data is discussed in an FOI Summary that may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
Start List of SubjectsList of Subjects
21 CFR Part 522
- Animal drugs
21 CFR Part 558
- Animal drugs
- Animal feeds
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 522 and 558 are amended as follows:
Start PartPART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS
End Part Start Amendment Part1. The authority citation for 21 CFR part 522 continues to read as follows:
End Amendment Part Start Amendment Part2. In 522.313a, revise paragraphs (e)(2)(i), (e)(2)(ii), and (e)(2)(iii) to read as follows:
End Amendment PartCeftiofur crystalline free acid.* * * * *(e) * * *
(2) * * *
(i) Amount. For subcutaneous (SC) injection in the posterior aspect of the ear where it attaches to the head (base of the ear) in lactating dairy cattle. For SC injection in the middle third of the posterior aspect of the ear or in the base of the ear in beef and non-lactating dairy cattle.
(A) Single-dose regimen: 6.6 mg ceftiofur equivalents per kg of body weight as a single injection.
(B) Two-dose regimen: 6.6 mg ceftiofur equivalents per kg of body weight given as two injections in the base of the ear approximately 72 hours apart.
(ii) Indications for use—(A) Single-dose regimen: For the treatment of bovine respiratory disease (BRD, shipping fever, pneumonia) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni in beef, non-lactating dairy, and lactating dairy cattle. For the control of respiratory disease in beef and non-lactating dairy cattle which are at high risk of developing BRD associated with M. haemolytica, P. multocida, and H. somni. For the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii in beef, non-lactating dairy, and lactating dairy cattle.
(B) Two-dose regimen: For the treatment of acute metritis (0-to 10-days postpartum) associated with bacterial organisms susceptible to ceftiofur in lactating dairy cattle.
(iii) Limitations. Following label use as either a single-dose or 2-dose regimen, a 13-day pre-slaughter withdrawal period is required after the last treatment. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal.
* * * * *3. In 522.1014, revise paragraph (d)(1)(ii) to read as follows:
End Amendment PartGamithromycin.* * * * *(d) * * *
(1) * * *
(ii) Indications for use. For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis in beef and non-lactating dairy cattle; and for the control of respiratory disease in beef and non-lactating dairy cattle at high risk of developing BRD associated with M. haemolytica and P. multocida.
* * * * *PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS
End Part Start Amendment Part4. The authority citation for 21 CFR part 558 continues to read as follows:
End Amendment Part Start Amendment Part5. In § 558.625, add paragraph (b)(90) to read as follows:
End Amendment PartTylosin.* * * * *(b) * * *
(90) No. 016592: 100 grams per pound for use as in paragraph (f) of this section.
* * * * *Dated: April 26, 2012.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. 2012-10632 Filed 5-2-12; 8:45 am]
BILLING CODE 4160-01-P
Document Information
- Comments Received:
- 0 Comments
- Effective Date:
- 5/3/2012
- Published:
- 05/03/2012
- Department:
- Food and Drug Administration
- Entry Type:
- Rule
- Action:
- Final rule.
- Document Number:
- 2012-10632
- Dates:
- This rule is effective May 3, 2012.
- Pages:
- 26161-26162 (2 pages)
- Docket Numbers:
- Docket No. FDA-2012-N-0002
- Topics:
- Animal drugs, Animal feeds
- PDF File:
- 2012-10632.pdf
- Supporting Documents:
- » Freedom of Information Summary ANADA 200-543 Cefpodoxime Proxetil
- » Freedom of Information Summary ANADA 200-491, Loxicom (meloxicam)
- » Freedom of Information Summary ANADA 200-485, Meloxicam Injection (meloxicam)
- » Freedom of Information Summary NADA 200-496 96% Solution Growing chickens, turkeys and laying hens
- » Freedom of Information Summary NADA 200-534 Melengestrol acetate plus monensin USP plus tylosin phosphate
- » Freedom of Information Summary NADA 141-068 BAYTRIL 100 Injectable Solution
- » Freedom of Information Summary NADA 141-346 OroCAM
- » Freedom of Information Summary NADA 141-344 VERAFLOX Suspension for Cats
- » Freedom of Information Summary ANADA 200-466 SPARMECTIN Plus Clorsulon
- » Freedom of Information Summary NADA 141-342 ALFAXAN
- CFR: (3)
- 21 CFR 522.1014
- 21 CFR 558.625
- 21 CFR 522.313a